Preventive health: which startup is ahead?

Which preventive-health startups belong in this race?

Preventive health currently has eight startups worth comparing closely: Neko Health, Function Health, Prenuvo, Everlab, Superpower, Fountain Life, Biograph and Q Bio.

We include companies that build a broad health baseline from several types of data and then help customers interpret or track it. The mix can include blood biomarkers, imaging, skin checks, cardiovascular measurements, genetics, wearables and medical records. We exclude wearables such as Oura and Whoop, single-purpose tests such as GRAIL’s cancer assay, and older providers such as Human Longevity. Ezra also drops out as a separate competitor because Function Health acquired it.

The category needs a clear boundary. Neko runs an integrated physical checkup. Function and Superpower begin with laboratory memberships. Prenuvo specializes in whole-body MRI. Everlab coordinates diagnostics and follow-up through a provider network. Fountain Life and Biograph sell expensive, physician-heavy programs. Q Bio is rebuilding the physical exam around MRI, biomarkers, genetics and longitudinal records. These companies compete for the same customer demand, but their products work very differently.

Funding figures below are approximate because private-market databases treat debt, older seed rounds and currency conversion differently. We use the most credible cumulative figure available and flag cases where the total remains less certain.

Startup	What it sells	Approximate cumulative funding
Neko Health	One-hour clinic check covering skin, heart, blood and metabolic health, followed by a clinician consultation	About $1.03B from a €60M Series A, a $260M Series B and a $700M Series C
Function Health	Membership with 160+ lab tests, clinician-reviewed insights, health tracking and optional imaging	About $351M
Prenuvo	Whole-body MRI screening, biomarker testing and recurring preventive-health memberships	About $275M, including debt in the database total
Q Bio	A physical exam combining whole-body MRI, biomarkers, genetics, wearables and physician review	About $80M
Everlab	A preventive-care platform linking diagnostics, doctors, specialists, prescriptions and ongoing follow-up	About $56M across its seed and Series A rounds
Biograph	Premium preventive assessments with imaging, cardiovascular testing and long-term clinical support	About $53.9M according to PitchBook data reported by SFGATE
Fountain Life	High-end longevity memberships combining imaging, biomarkers, physicians and selected treatments	About $52M, although published database totals vary
Superpower	Low-cost laboratory membership with 100+ biomarkers, a digital plan and continuous care-team access	About $51M

Is Neko Health really ahead in preventive health today?

Neko Health is currently ahead overall, with Function Health close enough to make this a real two-company race.

Neko has the most convincing combination of demand, repeat use and product ownership. The company controls its hardware, software and clinical workflow, while a large completed-scan base and heavy registration demand show that the clinic experience has moved well beyond an experiment. Its latest financing valued the business near $7 billion and gave it enough capital to open in the United States while expanding further in Europe.

Function is stronger on reach and price. The company says it serves hundreds of thousands of members, charges $365 a year and works through more than 2,000 US laboratory locations. It has also bought Ezra for imaging and Getlabs for at-home blood collection. Function can reach a new city through partners far faster than Neko can build and staff a clinic.

Prenuvo sits in third place because its lead is concentrated in one large part of the category. The company has built the biggest dedicated whole-body MRI operation, yet its product remains more expensive and narrower than a complete preventive-care relationship. Its new memberships add blood testing and year-over-year guidance, bringing Prenuvo closer to Neko and Function than it was a year ago.

Neko has the best complete product today, and Function has the easiest path to mass distribution. We keep Neko in front because customer commitment and control of the full experience carry more weight than raw geographic availability in a healthcare service that still needs to earn trust. That is the trade-off, really.

If you want more recent data on this point, please see our latest longevity market report.

Which preventive-health startup has the strongest real-world demand and growth?

Function Health probably has the largest preventive-health customer base; Neko Health shows the strongest paid demand per physical location.

Function describes its membership as numbering in the hundreds of thousands. Its website now reports more than 75 million results delivered to members. Dividing that figure by the advertised 160 annual tests gives roughly 469,000 full annual test sets. The real number of membership-years will differ because panels vary and testing is split across visits, but the calculation confirms that Function is operating at substantial consumer scale.

Neko has completed more than 100,000 assessments across eight clinics. That works out to more than 12,500 assessments per current clinic on a cumulative basis. The 350,000 people who have registered or joined a waitlist equal about 3.5 times the number already scanned, even after Neko expanded its clinic count fivefold. Demand is still running ahead of capacity.

Prenuvo has now performed more than 170,000 whole-body screenings across three continents. That puts its delivered imaging volume above Neko’s completed assessments, although the services cover different medical needs. Prenuvo also employs or works with more than 200 medical professionals, showing that the company has built a substantial radiology operation.

Everlab is smaller but moving quickly. The company reports 20,000 patients, more than 40,000 consultations, 21 million biomarker results and over 200,000 health reports processed each month. The monthly report figure is ten times its cumulative patient count, supporting Everlab’s claim that repeated care and data coordination now drive the product.

The gap below these four is large. Biograph says it has served thousands of clients, Fountain Life has a small premium-center network, Q Bio still delivers directly through one flagship clinic and selected partners, and Superpower has yet to publish a clean paid-member count. Those businesses may have strong products, but the disclosed usage data leaves them below the leading group.

Do customers come back for another preventive-health check?

Neko Health has the best public retention evidence in preventive health, and nobody else currently shows a comparable renewal number.

At the end of a first Neko appointment, 75% of members reportedly book and prepay for the following year’s scan. Prepayment makes the figure much stronger than a waitlist or an automatically renewing subscription. The customer has already spent an hour in the clinic, seen the results and still chooses to return.

Neko has also studied 1,469 customers who completed a second annual assessment. The company reported improvements in blood pressure, cholesterol and blood sugar across that returning group. The analysis remains company-produced and returning customers may be more motivated than average, but the cohort proves that repeated use already exists at meaningful scale.

Function, Superpower and Prenuvo all sell recurring relationships, yet none publishes a directly comparable renewal rate. Prenuvo only launched its current membership structure recently, so a mature annual-retention cohort would be difficult to show at this stage. Function’s large membership and rising test volume suggest continued use, but that remains weaker evidence than a disclosed renewal percentage.

This is Neko’s clearest edge over Function. Function may already reach more people, but Neko has shown that customers who finish the full experience are willing to pay for it again.

If you want more recent data on this point, please see our latest longevity market report.

Which preventive-health product is ready to scale now?

Function Health has the easiest preventive-health model to scale today; Neko Health still offers the most complete clinic product.

Function can use more than 2,000 Quest locations for laboratory work, offer home collection through Getlabs and sell MRI or CT scans through the Ezra network. Most of the expensive physical infrastructure already exists. Function mainly has to coordinate access, standardize the member experience and make the data useful.

Neko faces a heavier rollout. Each opening requires proprietary devices, suitable real estate, trained staff and local medical approvals. That slower expansion buys Neko tighter quality control. Its largest London center was designed for up to 30,000 scans a year, and newer Neko devices increase automation so clinical staff can spend more time with members.

Prenuvo has already shown that a complex imaging service can expand across three continents. Its challenge is keeping protocols, image quality and radiologist interpretation consistent across a growing network. The company now emphasizes structured reporting, dedicated whole-body readers and a team of more than 200 medical professionals. Those are company claims, but they address the correct operational bottlenecks.

Everlab offers a fourth route. Its platform connects to more than 1,850 provider locations, 180 active clinicians and over 30 wearable devices. The network gives Everlab broad capacity without forcing it to own every scanner or clinic. Consistency will become harder as the company enters new countries, especially when care involves different laboratories, specialists and medical rules.

Q Bio remains much earlier operationally. Its 75-minute exam is commercially bookable in Redwood City and available through enterprise partners, but the company has disclosed no patient volume that would show large-scale delivery.

Startup	Product maturity	How it scales	Main constraint
Function Health	Fully commercial across the US	Existing labs, imaging partners and home collection	Turning several partners into one coherent care experience
Neko Health	Fully commercial in the UK and Sweden, with US entry underway	Repeatable owned clinics using proprietary devices	Clinic construction, approvals and medical staffing
Prenuvo	Fully commercial across three continents	Dedicated and partner MRI locations	Price, radiology capacity and protocol consistency
Everlab	Commercial across Australia and New Zealand, with UK expansion planned	Large provider and clinician network	Maintaining consistent care across markets
Superpower	Nationally available laboratory membership	Quest locations and digital care	Limited public data on paid usage and retention
Fountain Life	Mature premium service	Owned centers and high-touch teams	Very high price and staff intensity
Biograph	Mature premium assessment in two cities	Owned clinics and specialist follow-up	Small footprint and expensive memberships
Q Bio	Commercial but early	Flagship clinic plus enterprise partners	One disclosed clinic and opaque patient volume

Which preventive-health startup gives customers the best value?

Function Health offers the strongest value across preventive health today.

Function charges $365 a year for more than 160 laboratory tests, testing across at least two visits, clinician-reviewed findings and a personalized plan. The advertised price equals about $2.28 per listed annual test before counting the software and medical review. That arithmetic oversimplifies laboratory economics, but it shows how far Function has pushed broad testing below traditional executive-health prices.

Superpower costs $199 a year and includes more than 100 biomarkers, a care team and access through thousands of Quest locations. Its price per listed marker falls below $2, although the standard membership includes one annual blood draw, whereas Function splits testing across at least two visits. Superpower is the cheapest credible broad laboratory product in the field.

Neko charges £299 in the UK for a one-hour assessment, same-day results and a clinician consultation. Function and Superpower provide more laboratory breadth, but neither recreates Neko’s skin imaging, cardiovascular measurements, custom devices and in-person explanation in one visit. For a physical clinic product, £299 is unusually aggressive.

Function also changed the imaging price curve after buying Ezra. Its AI-assisted full-body MRI starts at $499 and takes as little as 22 minutes. Prenuvo argues that cheap and expensive whole-body scans can differ sharply in protocol and interpretation, so price alone settles too little. Even so, Function has made an imaging baseline accessible to a much wider group.

The premium clinics serve another customer entirely. Biograph charges about $7,500 to $15,000 a year, while Fountain Life lists its APEX membership at $21,500. Those programs include more physician time and deeper follow-up, but their prices keep them outside the mass preventive-health race.

If you want more recent data on this point, please see our latest longevity market report.

Which preventive-health startup has the strongest medical evidence?

Prenuvo currently has the strongest formal research program, but no startup has proved that broad screening improves long-term outcomes for the average healthy customer.

Prenuvo says its research program has produced more than 50 peer-reviewed papers, abstracts and conference presentations. Its most discussed cancer study followed about 1,000 self-paying people: radiologists flagged 41 potentially cancerous findings, and follow-up reportedly confirmed cancer in roughly half, giving an overall detection rate near 2.2%. Two thirds of the detected cancers were in organs without routine population screening.

The study still leaves the hardest question unanswered. Finding more abnormalities helps only when earlier detection improves treatment or survival enough to outweigh biopsies, repeat scans, anxiety and overdiagnosis. Prenuvo’s Hercules study plans to follow 10,000 people over ten years, which could give the company a much stronger answer.

Neko’s evidence is more focused on what happens after a broad physical assessment. In a separate dataset of 4,362 Stockholm scans, the company reported that 1.2% revealed a previously unknown life-threatening condition requiring urgent care. Its returning-member analysis later found improvement across five of seven key biomarkers. Both datasets are useful, although Neko produced the analyses itself and neither uses a randomized control group.

Independent medicine remains cautious. The American College of Radiology says the evidence remains insufficient to justify total-body MRI screening for asymptomatic people without relevant risk factors or family history. A recent systematic review reached the same broad conclusion: whole-body MRI can detect cancers in healthy populations, while standardization, downstream follow-up and proof of better outcomes remain incomplete.

Prenuvo leads the evidence race, Neko has the best repeat-use outcomes data, and the decisive survival study that could change routine medical practice is still missing. Quite a big gap.

Who actually helps when a preventive-health test finds something?

Neko Health gives the clearest same-day medical handoff at a mass-market price.

Every Neko assessment ends with a clinician explaining the findings during the same visit. Customers leave with context and avoid facing a dashboard full of unexplained red flags on their own. Neko’s scope is narrower than the deepest luxury programs, but the handoff is built into a £299 product instead of a five-figure membership.

Everlab coordinates diagnostics, physicians, specialists, prescriptions and ongoing care through one platform. The company works with more than 180 active clinicians and names Boston Consulting Group, BHP and Bain & Company among its corporate customers. Those clients give Everlab the strongest disclosed employer validation in the group.

Function says clinicians review every result and flag issues, then the platform creates protocols for the member. The company provides interpretation and easier access to testing, while diagnosis and treatment still depend on independent medical providers. Its next challenge is making laboratory tests, imaging, home visits and outside care feel like one continuous relationship.

Prenuvo includes a provider review and has partnered with care companies such as Baker Health and Parsley Health. The arrangement improves the path from imaging to follow-up, although many findings still need referral into another medical system.

Biograph and Fountain Life provide the deepest hands-on care. Biograph uses multidisciplinary testing and connects members with specialists when needed. Fountain Life combines imaging, biomarkers, physicians and continuous access. Their clinical depth is real, but the price and small center count keep them in the luxury end of the market.

Which preventive-health product is hardest to copy?

Neko Health owns the hardest complete preventive-health product to reproduce.

Neko designs its own devices, software and clinical protocols, then delivers them through controlled clinics. A competitor would have to reproduce several capabilities together: medical hardware, automated measurement, clinic workflow, regulatory approval, clinician training and a consumer experience that encourages annual return. Buying laboratory capacity from a partner would solve only one small piece.

Prenuvo’s advantage comes from experience inside a specific medical modality. More than 170,000 screenings create a large archive of whole-body images and follow-up cases. The company also uses dedicated protocols, structured reporting and radiologists who spend much of their time reading screening scans. These points come from Prenuvo, yet the underlying scale is difficult for a new imaging brand to reproduce quickly.

Function’s physical inputs are easier to access because Quest, imaging centers and mobile phlebotomy already exist. Its defensibility is moving toward another layer: a large longitudinal dataset, a trusted consumer brand and the ability to join blood results, imaging, wearables and records in one interface. The acquisitions of Ezra and Getlabs speed up that integration and remove two potential partners or competitors from the field.

Q Bio may have the most ambitious technical architecture after Neko. Its exam combines whole-body MRI, biomarkers, genetics, wearables and physician review, and its FDA-cleared Constellation software supports MRI analysis. Commercial proof remains limited to a flagship clinic and partner deployments, so the technology has yet to become a scale advantage.

The product-performance question stays partly open because these services measure different things. Neko offers far less anatomical detail than a dedicated MRI, while Prenuvo leaves out blood testing and skin examination. No independent head-to-head study shows one complete service finding more clinically useful disease with fewer false alarms. We can rank defensibility today with more confidence than diagnostic superiority.

If you want more recent data on this point, please see our latest longevity market report.

Who is using preventive-health funding most efficiently?

Function Health has converted capital into reach more efficiently than Neko Health so far, with Prenuvo also showing strong delivery relative to funding.

Function has raised about $351 million and says it serves hundreds of thousands of members. Using 200,000 as the lowest literal reading gives no more than about $1,755 of cumulative funding per member. The true figure would be lower if the active base sits well above 200,000.

Prenuvo’s estimated $275 million divided by more than 170,000 screenings equals roughly $1,620 per delivered scan. Everlab’s estimated $56 million divided by 20,000 patients comes to about $2,800 per patient. These ratios measure capital intensity rather than customer acquisition cost, revenue or profitability, but they help compare how much real-world activity has followed the funding.

Neko’s roughly $1.03 billion divided by 100,000 completed assessments produces about $10,300 per historical scan. The ratio looks heavy because the latest round is meant to fund future US and UK clinics, while older capital paid for years of device development and regulatory work. Even with that allowance, Neko now carries the highest burden of proof in the sector.

Superpower has raised about $51 million but provides no clean member count, while Biograph and Fountain Life disclose too little financial or customer data for a useful comparison. Q Bio has raised about $80 million and still operates directly through one disclosed flagship clinic. The lack of disclosure is a problem for these lower-ranked companies. They have yet to show that their capital has produced reach comparable with Function, Prenuvo, Neko or Everlab.

Function is the clear funding-efficiency leader. Neko still ranks first across the whole category because its product and retention are stronger, but Function has stretched each dollar across far more accessible infrastructure.

Which preventive-health startup has the strongest momentum now?

Neko Health has the strongest preventive-health momentum now.

Neko recently raised $700 million, reached a valuation near $7 billion and prepared its first US clinic in New York. The company has also added body-composition measurements, Apple Health integration and a new generation of in-house devices with greater automation. Funding, geographic expansion and product development are moving together, making Neko’s acceleration broader than one financing headline.

Function’s momentum comes from assembling a larger platform. The company lowered its annual price, bought Ezra, bought Getlabs and pushed its reported result count above 75 million. Those moves broaden Function from a laboratory membership into a distributed preventive-health system with blood collection, imaging and software under one brand.

Everlab has just raised AU$65 million at a reported valuation approaching AU$500 million and is using the money to enter the UK. Its platform already processes more than 200,000 reports a month through a large provider network. If UK demand follows Australia and New Zealand, Everlab can move from regional contender to serious global challenger quickly.

Prenuvo has lately shifted from selling a scan toward selling an annual relationship. Its membership combines whole-body MRI, blood biomarkers and clinical guidance, while the London opening gives the company a first owned European base. Prenuvo is moving in the right direction, although Neko and Function are currently changing faster across more parts of their businesses.

Four developments could change the ranking. Function could move into first place by disclosing strong retention and making its partner network feel seamless. Neko could lose ground if US clinic costs or approvals slow the rollout. Prenuvo could jump higher if its long-term research shows better outcomes and opens reimbursement. Everlab could enter the top three by repeating its Australian operating results in the UK.

Which preventive-health startups are actually ahead?

Neko Health is the preventive-health startup ahead overall today, followed closely by Function Health and then by Prenuvo.

We put Neko first because it combines a differentiated product, substantial paid use, unusually strong disclosed repeat demand, same-day clinical interpretation and the hardest system to copy. Function is the closest challenger because it reaches more people, costs less and can expand through existing infrastructure. The gap is meaningful but small enough to reverse if Function proves retention or Neko struggles to reproduce its European experience in the United States.

Prenuvo owns third place through clear leadership in whole-body MRI. Everlab follows because its provider network, employer customers and recent expansion give it more commercial weight than the remaining startups. Superpower has the best low-cost challenge, although its customer disclosures remain thin. Fountain Life and Biograph lead the luxury end of the market. Q Bio has impressive technology and very limited disclosed scale.

The field has one leader, one close challenger and one strong specialist. Neko is ahead now, Function has the clearest route to catch it, and Prenuvo can still reshape the ranking if whole-body MRI earns stronger clinical backing.

Rank	Startup	Why it ranks here
1	Neko Health	Best overall mix of product quality, customer commitment, medical handoff, defensibility and current momentum
2	Function Health	Largest probable membership, strongest value and easiest national scaling model; retention remains the biggest missing proof point
3	Prenuvo	Clear whole-body MRI leader with the deepest imaging scale and research program, held back by price and unresolved population-screening evidence
4	Everlab	Strongest emerging care platform, with real employer customers, a large provider network and credible international momentum
5	Superpower	Cheapest broad laboratory membership and a potentially powerful mass-market position, with too little disclosed traction to rank higher
6	Fountain Life	Deep diagnostics and ongoing care across a growing premium-center network, but far too expensive for broad leadership
7	Biograph	Clinically rich assessment and specialist follow-up, constrained by two locations, premium pricing and limited public operating data
8	Q Bio	Ambitious multimodal exam and proprietary software, with commercial scale still concentrated in one flagship clinic and selected partners	" "# Preventive health: which startup is actually ahead?

If you want more recent data on this point, please see our latest longevity market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.